CLL
From the Journals
‘Highly encouraging’ MRD results for zanubrutinib add-on in CLL
Blood and bone marrow MRD was undetectable in almost 90% of subjects after a median of 10 treatment cycles.
From the Journals
CLL and COVID-19: Outcome trends and lessons learned
Data highlight opportunities for further investigation into optimal management of COVID-19, immune response after infection, and effective...
From the Journals
Venetoclax heralded a new class of small-molecule blood cancer drugs
BCL2 inhibitor venetoclax has been quickly followed by drugs that target either BCL2 or proteins with similar prosurvival function, especially...
Latest News
New trials in leukemia: Could your patient benefit?
Late-phase trials are opening up for leukemia patients aged 1-65 years.
Latest News
Decades spent searching for genes linked to rare blood cancer
Tantalizing clues about WM and related B-cell cancers have emerged.
From the Journals
BTKi resistance: ‘Achilles’ heel’ in effective treatment of B-cell malignancies
Success of BTKi in treating lymphoid malignancies is marred by resistance
From the Journals
Transfusions, readmissions higher for patients with CLL after cardiac surgery
From the Journals
Targeted CLL treatments found effective in managing associated autoimmune cytopenias
Conference Coverage
GLOW: Ibrutinib+venetoclax shines in first line for CLL/SLL
From the Journals
Patients with CLL have significantly reduced response to COVID-19 vaccine
Less than half of CLL patients had an antibody-mediated response to the Pfizer vaccine in a study.
Conference Coverage
Pediatric cancer survivors at risk for opioid misuse